It significantly decreased tumor proliferation and expression of surface activation markers CD69 and CD86 in chronic lymphocytic leukaemia which has similar clinical manifestations to MCL.39 This evidence concerns the gene CD86 and B-cell chronic lymphocytic leukemia.